Company intelligence / Profile preview
Vanarix
Lausanne, Vaud, Switzerlandvanarix-cartilage-regeneration.ch ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Vanarix has completed recruitment for a First-In-Man study with Autologous Cartibeads™ that began in 2022, with preliminary data indicating initial safety and efficacy in treating knee cartilage lesions. A First-In-Man study for Allogeneic Cartibeads™ is ongoing, with recruitment expected to be completed in 2024[1]. In December 2022, they reported their first successful transplantation[5]. In January 2025, Vanarix obtained Orphan Disease Designation from the FDA[5].
- Therapeutic areas
- Rheumatology
- Modalities
- Cell therapyTissue engineering
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Vanarix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanarix.